患者由来がん組織移植片（PDX）モデルを用いたin vivoおよびin vitroにおける薬効評価

DOI Web Site
  • 常住 真一郎
    株式会社ＬＳＩメディエンス　　創薬支援事業本部　試験研究センター薬理研究部
  • 柿沼 秀明
    株式会社ＬＳＩメディエンス先端事業推進部
  • 森川 崇
    株式会社ＬＳＩメディエンス　　創薬支援事業本部　試験研究センター薬理研究部
  • 榎 成憲
    株式会社ＬＳＩメディエンス　　創薬支援事業本部　試験研究センター薬理研究部
  • 片山 誠一
    株式会社ＬＳＩメディエンス　　創薬支援事業本部　試験研究センター薬理研究部
  • 嶋田 有紀子
    株式会社ＬＳＩメディエンス先端事業推進部
  • 井上 裕章
    株式会社ＬＳＩメディエンス先端事業推進部
  • 野村 大成
    国立研究開発法人医薬基盤・健康・栄養研究所難治性疾患研究開発・支援センター疾患モデル小動物研究室

書誌事項

タイトル別名
  • Evaluation of drug efficacy <i>in vivo</i> and <i>in vitro</i> using patient-derived xenograft (PDX)

説明

<p>To improve the success rate of anti-cancer drug development, clinically relevant tumor models are needed. Patient-derived xenograft (PDX) tumor, which is generated by direct implantation of human tumor into immunodeficient mice, has been well-accepted as a more clinically relevant model than cell line-derived xenograft (CDX) tumor. </p><p>We have been developing both in vivo and in vitro screening systems for anti-cancer drugs using PDX tumors that had been established in the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN). In this study, we confirmed anti-cancer drug efficacy using PDX in vivo and in vitro. </p><p>In the in vivo study, the PDX tumor was subcutaneously transplanted into immunodeficient mice, and a control group and drug group were set.  Gemcitabine or 5-FU was administered once or twice a week, and observation was carried out until 28 days after starting administration. Anti-cancer effect was evaluated by tumor volume.</p><p>In the in vitro study, three-dimensional culture was performed using dispersed cells derived from PDX tumor.  Drugs were added to the medium and the cell viability was confirmed by ATP assay.</p><p>In both studies, the effect of anti-cancer drug was confirmed, and an evaluation system in vivo and in vitro using PDX could be established.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ